Physician profile
Mark S King
NPI 1891882072
$4,056.93
in general payments reported to CMS, 2019-2025
18 companies · $418 in 2025
The $418 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $807 · 2020: $662 · 2021: $538 · 2022: $771 · 2023: $553 · 2024: $308 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,179 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.44 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,122.12 | 2019-2025 | Otezla |
| Janssen Biotech, INC. | $499.21 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $418.06 | 2019-2024 | Blu-U, Odomzo, Ilumya |
| Lilly USA, LLC | $404.18 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $318.45 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $248.00 | 2019-2022 | |
| Celgene Corporation | $204.07 | 2019 | |
| Novartis Pharmaceuticals Corporation | $191.94 | 2019-2025 | |
| Abbvie INC. | $182.22 | 2019-2025 | |
| Ucb, INC. | $123.21 | 2019-2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $105.76 | 2020-2021 | |
| Dusa Pharmaceuticals, INC. | $90.72 | 2019 | |
| Janssen Scientific Affairs, LLC | $45.12 | 2019-2022 | |
| Pfizer INC. | $38.15 | 2019-2022 | |
| Genentech USA, INC. | $20.30 | 2023 | Xolair |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $17.06 | 2022 | |
| Dermavant Sciences, INC. | $14.54 | 2023 | Vtama |
| Galderma Laboratories, L.P. | $13.82 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.